trending Market Intelligence /marketintelligence/en/news-insights/trending/mm7czH-kDc45D8XUnXATBg2 content esgSubNav
In This List

Ionis CEO to become executive chairman in 2020

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Ionis CEO to become executive chairman in 2020

Ionis Pharmaceuticals Inc. said founder and CEO Stanley Crooke will transition to executive chairman of the company's board of directors, effective January 2020.

Brett Monia, who has been COO for the previous year and a founding member of Carlsbad, Calif.-based Ionis, will take over from Crooke as CEO.

Crooke will continue to be in charge of board affairs and will provide strategic advice, as well as participate in the scientific activities of the company.

Ionis develops RNA-targeted therapies for genetic diseases such as spinal muscular atrophy, transthyretin amyloidosis and familial chylomicronemia syndrome.